We are live on ! Find out more
Connor, Clark & Lunn Investment Management (CC&L)

Connor, Clark & Lunn Investment Management (CC&L) Portfolio holdings

AUM $43.4B
1-Year Est. Return 51.29%
This Fund
S&P 500
This Quarter Est. Return
+1.73%
1 Year Est. Return
+51.29%
3 Year Est. Return
+133.48%
5 Year Est. Return
+173.9%
10 Year Est. Return
+551.09%
AUM
$22.9B
AUM Growth
+$801M
Cap. Flow
+$1.26B
Cap. Flow %
5.48%
Top 10 Hldgs %
26.16%
Holding
1,655
New
269
Increased
651
Reduced
446
Closed
272

Top Buys

Rank Stock Value
1
FNV icon
Franco-Nevada
FNV
+$159M
2
TRP icon
TC Energy
TRP
+$105M
3
MRVL icon
Marvell Technology
MRVL
+$92.4M
4
INFY icon
Infosys
INFY
+$83.4M
5
PAAS icon
Pan American Silver
PAAS
+$81.1M

Sector Composition

Rank Sector Weight
1 Financials 23.76%
2 Technology 17.69%
3 Industrials 12.67%
4 Energy 11.54%
5 Materials 11.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
NUE icon
226
Nucor
NUE
$61.8B
$16.5M 0.07%
137,080
+101,518
+285% +$13.1M
JAZZ icon
227
Jazz Pharmaceuticals
JAZZ
$16B
$16.4M 0.07%
132,415
+20,360
+18% +$2.66M
BPMC
228
DELISTED
Blueprint Medicines
BPMC
$16.3M 0.07%
183,947
+41,230
+29% +$4.02M
ORLY icon
229
O'Reilly Automotive
ORLY
$75.7B
$16.1M 0.07%
168,630
+57,990
+52% +$5.04M
MIRM icon
230
Mirum Pharmaceuticals
MIRM
$6.07B
$16.1M 0.07%
356,276
+179,316
+101% +$8.45M
OMCL icon
231
Omnicell
OMCL
$1.7B
$15.9M 0.07%
453,988
+24,301
+6% +$963K
TROW icon
232
T. Rowe Price
TROW
$23.9B
$15.9M 0.07%
172,709
+144,187
+506% +$15.2M
ENPH icon
233
Enphase Energy
ENPH
$5.32B
$15.8M 0.07%
254,672
+177,151
+229% +$11.2M
OPLN
234
Openlane
OPLN
$4.35B
$15.7M 0.07%
813,406
+126,683
+18% +$2.62M
NTCT icon
235
NETSCOUT
NTCT
$2.89B
$15.7M 0.07%
745,459
+146,848
+25% +$3.3M
SRPT icon
236
Sarepta Therapeutics
SRPT
$1.94B
$15.6M 0.07%
244,769
+97,533
+66% +$10.3M
EGO icon
237
Eldorado Gold
EGO
$10.1B
$15.6M 0.07%
928,596
-33,804
-4% -$508K
SKE
238
Skeena Resources
SKE
$4.05B
$15.4M 0.07%
1,524,038
+367,300
+32% +$3.7M
COST icon
239
Costco
COST
$421B
$15.4M 0.07%
16,249
-35,292
-68% -$34.4M
GEN icon
240
Gen Digital
GEN
$17.4B
$15.4M 0.07%
578,752
+248,018
+75% +$6.8M
LUMN icon
241
Lumen
LUMN
$6.42B
$15.1M 0.07%
3,856,417
-173,521
-4% -$865K
TGT icon
242
Target
TGT
$70.7B
$15M 0.07%
+144,157
New +$18M
RMD icon
243
ResMed
RMD
$32.8B
$15M 0.07%
67,106
+5,166
+8% +$1.21M
EXPE icon
244
Expedia Group
EXPE
$38.9B
$14.8M 0.06%
+88,007
New +$16M
HAL icon
245
Halliburton
HAL
$27.4B
$14.7M 0.06%
577,685
+292,748
+103% +$7.7M
VKTX icon
246
Viking Therapeutics
VKTX
$3.86B
$14.4M 0.06%
597,515
+222,293
+59% +$7.03M
HESM icon
247
Hess Midstream
HESM
$5.13B
$14.4M 0.06%
340,828
-62,087
-15% -$2.53M
ALLE icon
248
Allegion
ALLE
$14B
$14.3M 0.06%
109,390
+20,618
+23% +$2.67M
HAE icon
249
Haemonetics
HAE
$4.19B
$14.3M 0.06%
224,372
-27,770
-11% -$1.89M
CGAU
250
Centerra Gold
CGAU
$4.15B
$14.2M 0.06%
2,244,737
-265,200
-11% -$1.62M

Similar funds

Connor, Clark & Lunn Investment Management (CC&L)'s Q1 2025 Portfolio in Review

As of Q1 2025, Connor, Clark & Lunn Investment Management (CC&L) held 1,655 positions worth $22.9B, up 3.6% from $22.1B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Connor, Clark & Lunn Investment Management (CC&L) deployed $1.26B of net new capital in Q1 2025, opening 269 new positions and adding to 651 existing holdings. Its largest new stake was Advanced Micro Devices: 709,028 shares worth $72.8M.

By sector, the portfolio is most concentrated in Financials at 24% of assets, down from 26% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Celestica, an estimated $111M trimmed.

  • Connor, Clark & Lunn Investment Management (CC&L)'s largest Q1 2025 buy was Advanced Micro Devices: 709,028 shares worth $72.8M.
  • Connor, Clark & Lunn Investment Management (CC&L) added most to Franco-Nevada in Q1 2025, an estimated $159M increase.
  • Connor, Clark & Lunn Investment Management (CC&L)'s biggest Q1 2025 reduction was Celestica, cutting an estimated $111M.
  • Connor, Clark & Lunn Investment Management (CC&L) fully exited Edwards Lifesciences in Q1 2025, selling an estimated $28.1M.
  • Connor, Clark & Lunn Investment Management (CC&L)'s ten largest holdings make up 26% of its $22.9B portfolio in Q1 2025.
  • Connor, Clark & Lunn Investment Management (CC&L) opened 269 new positions and closed 272 in Q1 2025.
  • Connor, Clark & Lunn Investment Management (CC&L)'s portfolio value rose 3.6% quarter-over-quarter to $22.9B.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2025, filed 12 May 2025.